摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

6-(2-丙烯基)二氢麦角酸 | 81409-74-7

中文名称
6-(2-丙烯基)二氢麦角酸
中文别名
——
英文名称
(6aR,9R,10aR)-7-allyl-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinoline-9-carboxylic acid
英文别名
6-(2-propenyl)dihydrolysergic acid;cabergolinic acid;FCE21589;(9R)-7-allyl-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinoline-9-carboxylic acid;6-(2-propenyl)-ergoline-8β-carboxylic acid;6-allylergoline-8β-carboxylic acid;6-Allyl-8beta-carboxyergoline;(6aR,9R,10aR)-7-prop-2-enyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline-9-carboxylic acid
6-(2-丙烯基)二氢麦角酸化学式
CAS
81409-74-7
化学式
C18H20N2O2
mdl
——
分子量
296.369
InChiKey
YAICYXFUKKMAKO-XNRPHZJLSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    >160oC(dec.)
  • 沸点:
    530.4±50.0 °C(Predicted)
  • 密度:
    1.258
  • 溶解度:
    二恶烷(微溶)、DMSO、甲醇(微溶)

计算性质

  • 辛醇/水分配系数(LogP):
    0.3
  • 重原子数:
    22
  • 可旋转键数:
    3
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.39
  • 拓扑面积:
    56.3
  • 氢给体数:
    2
  • 氢受体数:
    3

SDS

SDS:591ef394f7ced15c2d6b1b0814f53f14
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    6-(2-丙烯基)二氢麦角酸 以70%的产率得到N-(2',6'-dimethyl-4-pyrimidyl)-6-allylergoline-8β-carboxamide
    参考文献:
    名称:
    Ergoline carboxamides
    摘要:
    提供了公式为:##STR1##的麦角碱衍生物,其中R.sub.1代表氢原子或甲基基团,R.sub.2代表氢原子、卤素原子或甲基基团,R.sub.3代表氢原子或甲氧基,R.sub.4代表碳原子数为1至4个的碳氢基团;X和W各自独立地表示氢原子、甲基基团、氯原子或甲氧基,n为0、1或2。还提供了它们的制备方法。这些化合物具有强的抗泌乳素活性。
    公开号:
    US04632990A1
  • 作为产物:
    描述:
    卡麦角林 在 sodium hydroxide 、 盐酸 作用下, 以 甲醇 为溶剂, 生成 6-(2-丙烯基)二氢麦角酸
    参考文献:
    名称:
    Synthesis of Novel Analogs of Cabergoline: Improving Cardiovascular Safety by Removing 5-HT2B Receptor Agonism
    摘要:
    The dopamine agonist cabergoline has been used to treat prolactinomas, Parkinson's disease, Cushing's disease, and sexual dysfunction. However, its clinical use was severely curtailed when it was found that patients taking cabergoline had an increased risk of developing cardiac-valve regurgitation. This potentially life-threatening condition has been associated with drugs, such as cabergoline, that are 5-HT2B receptor agonists. We prepared analogs of cabergoline and have identified several that have limited or no agonism at the 5-HT2B receptor.
    DOI:
    10.1021/ml3003814
点击查看最新优质反应信息

文献信息

  • New and efficient process for the preperation of cabergoline and its intermediates
    申请人:Wang Zhi-Xian
    公开号:US20080275240A1
    公开(公告)日:2008-11-06
    This invention relates to a new and efficient process for the production of dopamine agonists such as Cabergoline and the intermediates thereof.
    这项发明涉及一种用于生产多巴胺激动剂(如卡贝哌酮)及其中间体的新型高效工艺。
  • Synthesis of European pharmacopoeial impurities A, B, C, and D of cabergoline
    作者:Jernej Wagger、Aljaž Požes、Franc Požgan
    DOI:10.1039/c3ra43417f
    日期:——
    For the use of analytics, European pharmacopoeial impurities A, B, C, and D of cabergoline were synthesized. Ergocryptine was chosen as a starting material and synthesis was accomplished via two approaches, different in length and stereochemical outcome. A longer, indirect approach was realized through otherwise problematic oxidations of the 9,10-dihidrolysergol derivative, to the corresponding aldehyde and carboxylic acid. This was achieved by the use of activated DMSO and a Pinnick oxidation sequence. All four synthesized impurities are used as analytical standards in cabergoline manufacturing processes.
    为了使用分析技术,合成了欧洲药典中提到的卡贝缩脲的杂质A、B、C和D。选择了麦角隐碱作为起始材料,合成通过两种不同的途径完成,长度和立体化学结果各异。较长的间接途径通过对9,10-二氢麦角酰的衍生物进行问题较多的氧化反应,得到相应的醛和羧酸。通过使用活化的DMSO和Pinnick氧化序列实现了这一过程。所有四种合成的杂质均用于卡贝缩脲生产过程中作为分析标准。
  • New crystal form of cabergoline
    申请人:LEK Pharmaceuticals d.d.
    公开号:EP1953157A1
    公开(公告)日:2008-08-06
    The present invention relates to a new needle-form crystalline cabergoline form L, its preparation from halogenated aromatic solvents and aliphatic hydrocarbons and its use in pharmaceutical composition.
    本发明涉及一种新的针状结晶卡贝肌酮L型,它是通过卤代芳香溶剂和脂肪族烃制备的,并在制药组合物中使用。
  • Production of Cabergoline and Novel Polymorphic Form Thereof
    申请人:Greenwood Alan
    公开号:US20070197576A1
    公开(公告)日:2007-08-23
    The present application relates to a novel polymorphic form of cabergoline comprising cabergoline and t-amyl methyl ether, designated Form TAME cabergoline, together with a novel method of producing cabergoline.
    本申请涉及卡贝哌醇的一种新的多形态形式,包括卡贝哌醇和t-戊基甲醚,被称为TAME卡贝哌醇,以及一种新的生产卡贝哌醇的方法。
  • Process for the Preparation of Cabergoline
    申请人:Galambos Janos
    公开号:US20070293677A1
    公开(公告)日:2007-12-20
    A process for preparing cabergoline (I) from ergoline-8β-carboxylic acid ester (XIII) comprising the following steps. (XIII), (XVI), (XVII), (XVIII), (XIX), (I). The present case also relates to the intermediates (XVI), (XVII), (XVIII) and (XIX) as well as the polymorphic amorphous form of Cabergoline (I) and the production thereof.
    一种从麦角酸8β-羧酸酯(XIII)制备卡贝肯(I)的工艺,包括以下步骤:(XIII),(XVI),(XVII),(XVIII),(XIX),(I)。本案还涉及中间体(XVI),(XVII),(XVIII)和(XIX),以及卡贝肯(I)的多晶无定形形式及其生产。
查看更多